SEC Form 4 · accession 0001209191-17-014089
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Santosh Vetticaden
Officer — Interim CEO and CMO
Period of report
Feb 21, 2017
Accepted (ET)
Feb 23, 2017 · 9:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $12.65 | Feb 21, 2017 | A | 56,000 | A | — | Feb 20, 2027 | Common Stock | 56,000 | 56,000 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 21, 2017 | A | 14,000 | A | — | — | Common Stock | 14,000 | 14,000 | D |
Explanation of responses
- F1The option vests in 48 equal monthly installments and will be fully vested and exercisable on February 21, 2021.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on February 21, 2017. The RSUs vest in 3 equal annual installments beginning on February 21, 2018 and will be fully vested on February 21, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date.